

# Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

## Brilliant Violet 421(TM) anti-human CD19

RRID:AB\_2564227

Type: Antibody

---

### Proper Citation

BioLegend Cat# 363018, RRID:AB\_2564227

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2564227](http://antibodyregistry.org/AB_2564227)

**Proper Citation:** BioLegend Cat# 363018, RRID:AB\_2564227

**Target Antigen:** CD19

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC, IHC-F

**Antibody Name:** Brilliant Violet 421(TM) anti-human CD19

**Description:** This monoclonal targets CD19

**Target Organism:** human

**Clone ID:** Clone SJ25C1

**Antibody ID:** AB\_2564227

**Vendor:** BioLegend

**Catalog Number:** 363018

**Alternative Catalog Numbers:** 363017

**Record Creation Time:** 20231110T035209+0000

**Record Last Update:** 20260829T074726+0000

---

### Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD19.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD19.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Marceaux C, et al. (2026) TNF- $\alpha$ -mediated myeloid-instructed CD14+CD4+ T cells are associated with poor survival in lung adenocarcinoma. Cell reports. Medicine, 7(2), 102593.

Xu X, et al. (2024) Phase separation of chimeric antigen receptor promotes immunological synapse maturation and persistent cytotoxicity. Immunity, 57(12), 2755.